Amgen’s (AMGN) Modest Quarter
Amgen (AMGN) adjusted earnings per share of $1.12 for the first quarter of 2008, an increase of 4 % compared to $1.08 for the first quarter of 2007. Adjusted net income decreased 4 % to $1.218 billion in the first…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Amgen (AMGN) adjusted earnings per share of $1.12 for the first quarter of 2008, an increase of 4 % compared to $1.08 for the first quarter of 2007. Adjusted net income decreased 4 % to $1.218 billion in the first quarter of 2008 compared to $1.270 billion in the first quarter of 2007.
Amgen’s revenue decreased 2% during the first quarter of 2008 to $3,613 million versus $3,687 million in the first quarter of 2007.
Worldwide sales of Aranesp decreased 25% to $761 million in the first quarter of 2008. Sales of EPOGEN decreased 11% to $554 million.
Sales of Enbrel increased 30% in the first quarter to $951 million. Worldwide sales of Sensipar increased 27 % to $133 million.
The company guided for GAAP EPS for the year to be in a range of $3.66 to $4.01.
Douglas A. McIntyre
Contact [email protected] for any questions or corrections.